pharma
FibroGen names Lilly veteran as new CEO
January 7, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, fibrogen, pharma
Eli Lilly veteran Enrique Conterno has been revealed as the new Chief Executive Officer of FibroGen following the unexpected death …
FDA approves Glenmark’s generic version of Novartis’ Exjade tablets for chronic iron overload
January 7, 2020Manufacturing and Production, Research and Development Glenmark, exjade, generic, pharma
Indian pharma firm Glenmark has announced it has secured approval from the FDA for its oral deferasirox tablets in the …
Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma
January 7, 2020Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …
Teva to settle bribery lawsuit with $54 million payout
January 7, 2020Manufacturing and Production, Sales and Marketing Teva, bribery, pharma
Israeli drug firm Teva has agreed to settle an ongoing lawsuit levying allegations of the company’s bribery of doctors, it …
MHRA expands approval of Dysport for symptomatic treatment of focal spasticity of the upper limbs in paediatric cerebral palsy
January 6, 2020Sales and Marketing Dysport, MHRA, ipsen, pharma
Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …
Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease
January 6, 2020Research and Development, Sales and Marketing Incyte, pharma, trial failure
Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …
Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma
December 16, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …
A new weapon against Parkinson’s-related psychosis
December 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma
Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
December 16, 2019Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
December 16, 2019Research and Development, Sales and Marketing Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma
December 13, 2019Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma
The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …
Top Ten most popular articles on Pharmafile.com this week
December 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten
As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
Latest content
Five Facts about cardiovascular disease
